(Photo by Lucigerma on Shutterstock)
Could Ultrasound Replace Pain Medication? New Brain Study Offers Early Clues
In A Nutshell
- Researchers used focused sound waves delivered through the skull to stimulate a deep brain region involved in pain processing, with no surgery or drugs required.
- Participants who received real ultrasound showed a greater drop in pain ratings between 28 and 55 minutes after stimulation compared to those who received a fake treatment, suggesting pain relief may build after the device is switched off.
- Brain scans revealed that the ultrasound rewired how key pain-related brain regions communicate with each other, and only while participants were actively experiencing pain, not at rest.
- The study was conducted in healthy adults, not chronic pain patients, and the pain-relief finding was marginal, so researchers say larger follow-up studies are needed before any clinical use.
Pain is one of medicine’s most stubborn problems. Chronic pain affects millions of Americans, and existing treatments, from opioids to surgery, often fall short or come with serious downsides. So the search for drug-free, non-surgical options has become one of the most active frontiers in brain science. Research from the University of Plymouth and the University of Exeter, published in Nature Communications, may have found a promising path forward.
The study focuses on aiming focused sound waves at a specific brain region involved in processing pain, with results suggesting the brain’s pain-related networks shift in response, and that relief may continue building even after the sound waves stop.
The technique is called transcranial ultrasound stimulation, or TUS, a non-invasive method of nudging brain activity using focused sound waves delivered through the skull. No incisions are required. The target was a region deep in the brain called the dorsal anterior cingulate cortex, central to how the brain processes both the physical sensation of pain and its emotional weight, essentially how much that pain bothers a person.
Healthy Adults Received Either Real or Fake Ultrasound Stimulation
Thirty-two healthy adults took part in this randomized study. Each came in for two main sessions. In one, they received active ultrasound stimulation. In the other, they received a sham, a convincing imitation using the same equipment and matching sounds through headphones, but no actual brain stimulation. The researcher administering the stimulation was confirmed to be effectively blinded. Participants were not formally assessed for blinding, so it is unknown whether they could guess their condition, a limitation the authors acknowledge.
During each session, participants submerged their right hand in a cold gel, a standard method for inducing a tolerable, steady level of pain, while ultrasound pulses were delivered to three closely spaced points within the target region. Brain scans tracked changes in activity and connectivity. Pain ratings were collected at three points: during stimulation, about 28 minutes after, and again around 55 minutes after.
The device operated at 500 kilohertz, a frequency too high-pitched for humans to hear, and delivered stimulation for about four minutes total. All safety checks confirmed the stimulation stayed within established thresholds, verified with individualized computer modeling for each participant. Most reported side effects, such as mild tingling, slight dizziness, or sleepiness, were rated as mild and considered unlikely to be related to the stimulation.
Brain Scans Showed Rewired Pain Circuitry
No single snapshot of pain ratings showed a dramatic difference between the active and sham groups. But a closer look at how ratings changed over time told a different story. Between approximately 28 and 55 minutes after stimulation, participants who received active ultrasound showed a significantly greater drop in pain ratings compared to those who received the sham. The authors describe this as a potential “delayed analgesic effect,” pain relief that takes time to emerge. Because the margin of statistical significance was narrow and the sample was small, the researchers caution this finding needs replication before firm conclusions can be drawn.
Brain imaging added an important layer of detail. Active ultrasound increased coordination between the target region and several other brain areas involved in pain processing and movement planning. Connectivity with the periaqueductal grey, a region involved in the brain’s descending pain-control system, also shifted after active stimulation.
These connectivity changes appeared only during the cold pain session, not during rest or after the pain stimulus was removed. That points to state dependency: the brain region responds to the sound waves differently when it is already busy processing pain than when it is at rest.
The Ultrasound Scrambled How the Brain Reads Cold as Pain
One unexpected finding involved how the brain encodes pain intensity. Under normal circumstances, the colder the stimulus, the more pain a person reports. After active ultrasound, that relationship was no longer statistically clear. In the sham group, the expected pattern held firm. TUS may interfere with how the brain registers cold as painful, not just how distressing that pain feels.
A chemical analysis of the target region, conducted about 55 minutes after stimulation, found no overall group difference. But participants who showed a larger drop in GABA, a chemical that usually dampens brain activity, tended to report more pain relief at the later time point. This hints that people whose brains respond to TUS with greater excitation may experience stronger effects, though the researchers caution the observation needs replication.
One prior study in chronic pain patients found that TUS aimed at the same brain region reduced reported pain, with improvement lasting up to seven days after a single session, though the designs differ enough that direct comparison is not possible. What this research adds is a window into the machinery: brain scans showing exactly which circuits shift, and evidence that what researchers measure, and when, can be the difference between seeing an effect and missing one entirely.
For the tens of millions of Americans living with chronic pain who have run out of good options, a non-invasive technique delivered without drugs or surgery is an appealing prospect. This study does not yet prove TUS is ready for the clinic, but it offers some of the clearest mechanistic evidence to date that the brain’s pain circuitry can be meaningfully shifted by sound.
Disclaimer: This article is for general informational purposes only and does not constitute medical advice. Transcranial ultrasound stimulation for chronic pain is still experimental. Anyone experiencing chronic pain should consult a qualified healthcare provider about treatment options.
Paper Notes
Limitations
The authors acknowledge several important limitations. The sample size is relatively small, with 29 participants for the brain connectivity analysis and 23 for the chemical analysis, which limits statistical power and may affect how broadly the findings can be applied. Brain imaging data were affected by excessive noise in the combined multi-echo dataset, leading researchers to use only one echo time for analysis, potentially reducing sensitivity. A scanner software update midway through data collection required a modification to the scan sequence, potentially introducing additional variability. The relatively short scan duration was also noted as a limitation. Blinding was confirmed effective for the researcher administering stimulation, but blinding was not formally assessed for participants, which could introduce expectation-related bias. The researcher conducting data analysis was unblinded at that stage, which the authors note as a potential source of bias. All participants were healthy adults, not chronic pain patients, so generalization to clinical populations requires further research. The statistical significance for the delayed analgesic effect is marginal, and the authors state the finding requires replication.
Funding and Disclosures
Sam Hughes, Sophie Clarke, and Elsa Fouragnan are funded by a Neuromod+ grant. Elsa Fouragnan is also funded by a UK Research and Innovation Future Leaders Fellowship, a Biotechnology and Biological Sciences Research Council grant, and an Advanced Research and Invention Agency grant. Elsa Fouragnan is an advisor for Attune Neuroscience. The remaining authors declare no competing interests.
Publication Details
Authors: Sophie Clarke, Samuel Mugglestone, Mathilde Lojkiewiez, Joshua Marquez, Nadège Bault, Elsa Fouragnan, and Sam Hughes. Elsa Fouragnan and Sam Hughes are listed as equal senior contributing authors. Sophie Clarke is the corresponding author ([email protected]). Authors are affiliated with the School of Psychology and the Brain Research and Imaging Centre at the University of Plymouth, and the Department of Clinical and Biomedical Sciences at the University of Exeter, both in the United Kingdom. | Journal: Nature Communications | Paper Title: “Multi-focal ultrasound neuromodulation to the dorsal anterior cingulate cortex disrupts behavioural and neural pain processing” | DOI: https://doi.org/10.1038/s41467-026-72934-3 | Status: Article in press (unedited version). The manuscript has been accepted but has not yet undergone final editing. Errors affecting content may be present, and all legal disclaimers apply.







